Futura Medical: Investment Bank Affirms Performance Matches Claims

"Doing what it says on the tube" was the headline from a Panmure Liberum report following Futura Medical PLC's,(LSE:FUM),interim results.,The report h...

Arecor Therapeutics Presents Promising Data at Madrid Conference

Arecor Therapeutics PLC,(LSE:AREC),will present positive Phase I trial results for its ultra-concentrated, ultra-rapid-acting insulin, AT278, at the E...

AstraZeneca Shares Slide After Lung Cancer Trial Update

The share price of AstraZeneca,(LSE: AZN),experienced a significant decline on Tuesday following disappointing updates from the company's latest lung...

CVS Group Shares Rise Despite Intrinsic Value Gap

CVS Group plc, operating within the,healthcare sector,, has recently experienced a notable increase in its share price, rising over 10% on the AIM mar...

Futura Posts Early Maiden Profit, Revenue and Earnings to Surge

Futura Medical PLC,(LSE:FUM),has announced a significant milestone in its financial performance for the first half of 2024, marking its first profit o...

Futura Medical Hits Milestone with First Profit, Prepares for US Ero...

Futura Medical PLC (LSE:FUM) CEO James Barder recently discussed the company's latest financial performance and future outlook with Proactive's Stephe...

hVIVO CEO Highlights Record H1 Revenue and Strategic Expansion

hVIVO PLC,(LSE:HVO),CEO Yamin (Mo) Khan recently discussed the company’s notable achievements in the first half of 2024 with Proactive's Stephen Gunni...

ImmuPharma reports interim progress on lead asset

ImmuPharma PLC,(LSE:IMM),has reported progress in developing treatments for autoimmune diseases, with a focus on Systemic Lupus Erythematosus (SLE) an...

Hutchmed to Present New and Updated Clinical Trial Data

Hutchmed China,(LSE:HCM),has announced that it will present new and updated clinical trial data at two major oncology conferences: the 2024 World Conf...

RUA Life Sciences Acquires French Implantable Devices Company

RUA Life Sciences,(LSE:RUA),has completed the acquisition of implantable devices manufacturer Analytic Biosurgical Solutions for €80,000. The purchase...

Oncimmune Shares Surge Following Contract Wins

Shares in Oncimmune, a company specializing in autoantibody profiling, saw a significant rise on Monday after the firm reported strong commercial prog...

Hemogenyx Pharmaceuticals Reaches Critical Milestone

A prominent player of,Healthcare Sector,Hemogenyx Pharmaceuticals PLC has announced the successful development of a clinical-grade assay designed to m...

GSK Reports Positive Results from COPD Trial

On Friday, GSK,(LSE:GSK),reported positive results from its phase three ‘MATINEE’ clinical trial, which assessed the efficacy of ‘Nucala’ (mepolizumab...

GSK Reports Positive COPD Trial Results

Successful MATINEE Trial Results,GSK PLC,(LSE:GSK),has announced encouraging results from the Phase III clinical trial named MATINEE, which assessed t...

Indivior’s CUD Study Falls Short of Primary and Secondary Endpoints

On Wednesday, Indivior,(LSE:INDV),reported that the Phase 2B clinical trial conducted by Aelis Farma on the drug AEF0117 for treating cannabis use dis...

Aptamer Renews Contract with Unilever

On Tuesday, Aptamer,(LSE:APTA),, a company specializing in custom antibody alternatives, announced the extension of its contract with Unilever to adva...

Oxford Nanopore Shows Steady First Half Amid Market Challenges

On Tuesday, Oxford Nanopore Technologies,(LSE:ONT),reported a steady performance for the first half of the year, despite facing challenging market con...

Aptamer Group Gains Boost from Unilever Collaboration Extension

Shares of Aptamer Group PLC,(LSE:APTA),saw a 4% increase following the announcement of an extended contract with consumer giant Unilever PLC. The part...

Uniphar reports first-half growth in all its divisions

On Tuesday, Uniphar,(LSE:UPR),, an international diversified healthcare service provider, reported robust first-half financial results, showcasing sig...

Berenberg upgrades Hikma Pharmaceuticals

On Tuesday, Berenberg upgraded Hikma Pharmaceuticals,(LSE:HIK),, raising the price target from 2,100p to 2,400p, citing significant progress within th...